A double-blind placebo-controlled study assessing the efficacy and tolerability of 50 mg sumatriptan tablets in the acute treatment of migraine

International Journal of Clinical Practice, Supplement

Volumn , Issue 105, 1999, Pages 7-15

  Savani, Narenen ^a   Brautaset, Nils J ^a   Reunanen, Mauri ^b   Szirmai, Imre ^c   Ashford, Elizabeth A ^d   Hassani, Habib ^d   Saiers, Jane ^e  

^a Oulon Diakonissalaitos ^*

^b Glaxo Wellcome R and D   (Finland)

^c SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^d GLAXOSMITHKLINE   (United Kingdom)

^e GLAXOSMITHKLINE   (United States)

Author keywords

Acute migraine; Dosage; Efficacy; Oral sumatriptan; Safety

Indexed keywords

PLACEBO; SUMATRIPTAN; SEROTONIN AGONIST; VASOCONSTRICTOR AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; NAUSEA; ORAL DRUG ADMINISTRATION; PHOTOPHOBIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; VOMITING; ACUTE DISEASE; ADOLESCENT; AGED; MIDDLE AGED; MULTICENTER STUDY; RECURRENT DISEASE; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; RECURRENCE; SEROTONIN AGONISTS; SUMATRIPTAN; TREATMENT OUTCOME; VASOCONSTRICTOR AGENTS;

EID: 33749205615     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. The Oral Sumatriptan Dose-Defining Study Group. Sumatriptan: an oral dose-defining study. Eur Neurol 1991; 31: 300-305.
2. The Oral Sumatriptan International Multiple-Dose Study Group. Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. Eur Neurol 1991; 31: 306-313.
3. Cutler N, Mushet GR, Davis R et al. Oral sumatriptan for the acute treatment of migraine: evaluation of three dosage strengths. Neurology 1995; 45(Suppl 7): S5-S9.
4. Sargent J, Kirchner JR, Davis R et al. Oral sumatriptan is effective and well tolerated for the acute treatment of migraine: results of a multicenter study. Neurology 1995; 45(Suppl 7): S10-S14.
5. Nappi G, Sicuteri F, Byrne M et al. Oral sumatriptan compared with placebo in the acute treatment of migraine. J Neurol 1994; 241: 138-144.
6. Ferrari MD, James MH, Bates D et al. Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrences. Cephalalgia 1994; 14: 330-338.
7. Goadsby PJ, Zagami AS, Donnan GA et al. Oral sumatriptan in acute migraine. Lancet 1991; 338: 782-783.
8. Pfaffenrath V, Cunin G, Sjonell G et al. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan. Headache 1998; 38: 184-190.
9. Moschiano F, D'Amico D, Grazzi L et al. Sumatriptan in the acute treatment of migraine without aura: efficacy of 50 mg dose. Headache 1997; 37: 421-423.
10. Headache Classification Committee of the International Headache Society Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain. Cephalalgia 1988; 8: 1-96.
11. The Multinational Oral Sumatriptan and Cafergot Comparative Study Group A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. Eur Neurol 1991; 31: 314-322.
12. The Oral Sumatriptan and Aspirin Plus Metoclopramide Comparative Study Group. A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. Eur Neurol 1992; 32: 177-184.
13. Geraud GE. Evaluation of the long-term safety and efficacy of 311C90 in the treatment of migraine. Eur Neurol 1996; 36(Suppl 2): 24-27.